RxDoctor Payments Data

Brian Granger, DO

Family Medicine · Jacksonville, FLNPI 1366775280

Payments from drug & device makers

$17,353in general payments, 2019–2025

Across 769 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Amarin Pharma, Inc.$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • GSK$1K
  • plus $8K from 39 others

What the payments were for

  • Consulting fees$1,2007%
  • Food & beverage$15,97592%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,353 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$194,234
Medicare patients
336
Services billed
3,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide136$163,953
TrulicityDulaglutide92$97,975
JardianceEmpagliflozin76$90,874
EliquisApixaban93$85,740
OzempicSemaglutide40$50,398
VascepaIcosapent Ethyl41$33,736
FarxigaDapagliflozin Propanediol27$33,013
MyrbetriqMirabegron33$28,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,865
JanuviaSitagliptin Phosphate16$21,111
KerendiaFinerenone11$12,897
Icosapent Ethyl36$12,657
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,476
SymbicortBudesonide/Formoterol Fumarate17$6,734
Tresiba Flextouch U-100Insulin Degludec11$6,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,930$261,928228 claims
Boehringer IngelheimJardiance$404$90,87476 claims
PfizerEliquis$865$85,74093 claims
Novo NordiskOzempic$1,618$50,39840 claims
AstraZenecaFarxiga, Symbicort$1,607$39,74844 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,205$37,34154 claims
Astellas Pharma US IncMyrbetriq$359$28,25033 claims
MerckJanuvia$368$21,11116 claims
BayerKerendia$499$12,89711 claims
Sanofi-aventis U.S. LLCLantus$276$1,52412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →